The Effect of Nocturnal Dexmedetomidine on Postoperative Sleep Quality and Fatigue After Major Surgery in Elderly Patients: DEXSLEEP Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Placebo, Dexmedetomidine.
- Who it may be relevant to
- Registry conditions: Postoperative Fatigue, Postoperative Sleep Disturbances, Surgical Stress Response. Basic parameters: from 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
In the aftermath of major surgery, many patients suffer from pain, fatigue, reduced general well-being, and cognitive dysfunction. Another common concern after major surgery is sleep impairment and there is little known about its effect on postoperative morbidity, especially postoperative fatigue and muscle function. Dexmedetomidine has been shown to possibly improve postoperative sleep quality in critically ill patients. However, whether the administration of dexmedetomidine translates into reduced postoperative fatigue and/or weakness and improved enhanced recovery after surgery by improving sleep, is currently unknown. The DEXSLEEP study will evaluate the effect of nocturnal administration of dexmedetomidine, as compared to placebo (i.e. no dexmedetomidine), on postoperative quality of recovery, postoperative fatigue and muscle weakness.
Detailed description
Due to the increase in life expectancy in the developing world, the number of elderly patients undergoing (major) surgery is expected to increase in the coming years. These elderly patients, even healthy older adults, have a reduced physiologic reserve such that organ systems may be compromised during and after surgical stress, placing them at greater risk of morbidity and mortality after surgery.
A common concern after surgery is sleep impairment. Patients often develop significant sleep disturbances after major surgery and particular elderly patients are more prone to develop sleep disturbances when compared to younger patients. Sleep plays an essential role in the homeostasis of multiple organ systems and cognitive function. A good night sleep is deemed essential for a good functional recovery. Taking this into account, it seems logical that postoperative sleep disturbances could be a contributing factor to postoperative fatigue, which is reported by patients as one of the most distressing symptoms after surgery and is thought to be the chief contributor to delayed recovery after surgery.
The endocrinological surgical response probably plays an essential role in postoperative sleep disturbances experienced by surgical patients by causing (neuro)inflammation. Keeping this in mind, dexmedetomidine might be an interesting pharmacological intervention since it has the ability to attenuate several factors that contribute to postoperative sleep disturbances including the endocrinological surgical stress response. However, whether the nocturnal administration of dexmedetomidine translates into improved postoperative sleep quality after elective major surgery, subsequently reduced postoperative fatigue and muscle weakness, and improved enhanced recovery after surgery by improving sleep, is currently unknown.
Therefore, the main objective of this prospective clinical trial is to evaluate the effect of nocturnal dexmedetomidine on early postoperative outcomes, i.e. quality of recovery, in elderly patients (60 years or older) undergoing major surgery.
Interventions
- Drug Placebo
The comparator is a placebo, namely pure saline (NaCl 0.9%), which will be administered following the same regimen as the intervention. - Drug Dexmedetomidine
Nocturnal administration of dexmedetomidine (0.2-1.0 mcg/kg/h) during the first night after surgery. Dexmedetomidine infusion, not preceded by a bolus administration, will be started at 0.4 mcg/kg/h in the intervention group at 8 p.m. the day of surgery. Dexmedetomidine infusion will be titrated every 30 minutes with 0.1 mcg/kg/h steps until a RASS of -1 to -3 (drowsy, light to moderate sedation) is reached. The infusion will be discontinued at 6 a.m. the next morning.
Primary outcome measures
- Quality of Recovery (QoR) [Time frame: Pre-operative and postoperative day 1]
Secondary outcome measures (12)
- Sleep-wake cycle (MCTQ) [Time frame: 3 days before surgery]
- Sleep pattern (CSD) [Time frame: 10 consecutive nights, starting 3 days before surgery]
- Postoperative fatigue - Chalder fatigue questionnaire [Time frame: Pre-operative and postoperative day 1, day 3, day 5 and day 28]
- Health-related quality of life (EQ-5D) [Time frame: Pre-operative and postoperative day 28]
- Subjective sleep quality (PSQI) [Time frame: 3 days before surgery and postoperative day 28]
- Postoperative fatigue - Fatigue VAS scale [Time frame: Pre-operative and postoperative day 1, day 3, day 5 and day 28]
- Subjective sleep quality first night after surgery (RCSQ) [Time frame: Postoperative day 1]
- Postoperative delirium [Time frame: Postoperative day 1, day 3 and day 5]
- Postoperative cognitive impairment [Time frame: Pre-operative and postoperative day 28]
- Quality of Recovery (QoR) [Time frame: Pre-operative and postoperative day 3 and day 5]
- Postoperative muscle strength (upper extremity) [Time frame: Pre-operative and postoperative day 1, day 3 and day 5]
- Postoperative muscle strength (lower extremity) [Time frame: Pre-operative and postoperative day 3 and day 5]
Eligibility criteria
Inclusion criteria
- aged 60 years or older;
- scheduled for thoracoscopic lung surgery.
Exclusion criteria
- lack of informed consent or inability to give informed consent;
- ≥ 2nd-degree atrioventricular block without pacemaker;
- uncontrolled hypotension (blood pressure \< 90/60 mmHg);
- known hypersensitivity to dexmedetomidine or to any of the excipients;
- acute cerebrovascular conditions;
- urgent, not elective surgery.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Belgium · 1 center
- Ziekenhuis Oost-Limburg — Genk
Identifiers
NCT: NCT06480539 · Z-2023104